{"disease":{"id":"malignant-tumor-of-prostate","name":"Malignant tumor of prostate","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"enzalutamide","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xtandi","generic_name":"enzalutamide","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":"4500","mechanism":"Xtandi works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"enzalutamide","indication_name":"Metastasis from malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xtandi","generic_name":"enzalutamide","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":"4500","mechanism":"Xtandi works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"apalutamide","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erleada","generic_name":"apalutamide","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"","quality_score":65,"revenue":"2600","mechanism":"Erleada blocks the androgen receptor, a protein that helps cancer cells grow."},{"drug_id":"apalutamide","indication_name":"Metastasis from malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erleada","generic_name":"apalutamide","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"","quality_score":65,"revenue":"2600","mechanism":"Erleada blocks the androgen receptor, a protein that helps cancer cells grow."},{"drug_id":"abiraterone-acetate","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zytiga","generic_name":"abiraterone-acetate","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Steroid 17-alpha-hydroxylase/17,20 lyase","drug_class":"Cytochrome P450 17A1 Inhibitor","quality_score":64,"revenue":"1500","mechanism":"Zytiga blocks the production of male hormones that fuel prostate cancer growth."},{"drug_id":"relugolix","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orgovyx","generic_name":"relugolix","company_name":"MYOVANT SCIENCES","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist [EPC]","quality_score":72,"revenue":"421","mechanism":"Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors."},{"drug_id":"radium-ra-223-dichloride","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xofigo","generic_name":"RADIUM RA 223 DICHLORIDE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"","drug_class":"radium Ra 223 dichloride","quality_score":50,"revenue":"400","mechanism":"Xofigo works by emitting alpha particles that selectively target and kill cancer cells in the prostate."},{"drug_id":"xtandi","indication_name":"Metastasis from malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xtandi","generic_name":"xtandi","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen receptor inhibitor","quality_score":10,"revenue":null,"mechanism":"Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction."},{"drug_id":"docetaxel","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"radium","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radium bromatum","generic_name":"RADIUM","company_name":"Bayer Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Radium bromatum works by emitting ionizing radiation that damages cancer cells, preventing them from growing and dividing."},{"drug_id":"xofigo","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xofigo","company_name":"Bayer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"alpharadin","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Alpharadin","company_name":"M.D. Anderson Cancer Center","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxotere","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mdv3100","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MDV3100","generic_name":"mdv3100","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen","drug_class":"Androgen receptor inhibitor","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"mdv3100","indication_name":"Metastasis from malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MDV3100","generic_name":"mdv3100","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen","drug_class":"Androgen receptor inhibitor","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"zytiga","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zytiga","company_name":"Bukwang Pharmaceutical","drug_phase":"marketed","molecular_target":"Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xtandi","indication_name":"Malignant tumor of prostate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xtandi","generic_name":"xtandi","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen receptor inhibitor","quality_score":10,"revenue":null,"mechanism":"Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction."}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT06201078","title":"Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Maria Sklodowska-Curie National Research Institute of Oncology","has_results":false},{"nct_id":"NCT05653856","title":"Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Curium US LLC","has_results":true},{"nct_id":"NCT06982469","title":"High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT04091295","title":"BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Aveni Foundation","has_results":false}],"total":5},"guidelines":[{"drug_id":"docetaxel","guideline_body":"FDA label","recommendation":"Docetaxel in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}